Association between serum soluble ST2 level and right ventricle systolic function on pulmonary hypertension due to atrial septal defect

https://doi.org/10.19106/JMedSci005203202005

Firandi Saputra(1), Anggoro Budi Hartopo(2*), Hariadi Hariawan(3), Dyah Wulan Anggrahini(4), Lucia Kris Dinarti(5)

(1) Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada – Dr. Sardjito Hospital, Yogyakarta, Indonesi
(2) Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada – Dr. Sardjito Hospital, Yogyakarta, Indonesi
(3) Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada – Dr. Sardjito Hospital, Yogyakarta, Indonesi
(4) Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada – Dr. Sardjito Hospital, Yogyakarta, Indonesi
(5) Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada – Dr. Sardjito Hospital, Yogyakarta, Indonesi
(*) Corresponding Author

Abstract


Pulmonary hypertension (PH) due to atrial septal defect (ASD) may cause a decline in right ventricle (RV) function. Soluble ST2 isa prognostic biomarker for left ventricle dysfunction. However, its role in RV function has not been investigated. This study aimed to investigate the association between serumsoluble ST2 with RV systolic function in patients withASD–associatedPH. This was a cross sectional study. Subjects were patients participated in the COHARD-PH registry performed in Dr. Sardjito General Hospital, Yogyakarta Indonesia. The patients with ASD and PH confirmed by right heart catheterization (RHC) were enrolled in this study. The soluble ST2 level was measured in the serum collected from pulmonary artery during RHC. Right ventricle systolic function was determined by transthoracic echocardiography using peak systolic velocity of tricuspid annulus (S’) parameter. This study was performed in 32 adults with uncorrected ASD. They predominantly females [n=29 (90.6%)] with median age of 31(22.5-44.0) years old. Mean ASD diameter was 2.69±0.53 cm. Median mean pulmonary artery pressure (mPAP) 45.0 (36.25-70.0) mmHg. Median soluble ST2 level was 23.28 ng/mL. There were no significant correlations between soluble ST2 level with S’value (r=0.071; p=0.35), with mPAP (r=0.043; p=0.815), with pulmonary vasculer resistance (PVR) (r=0.025; p=0.893) and with right ventricle (RV) diameter (r=0.200; p=0.273). Soluble ST2 level was found higher in subject with RV dysfunctionbut not statistically significant. In conclusion, serum soluble ST2 level did not associate withRV systolic function, measured by S’, in adult ASD-associated PH.


Keywords


atrial septal defect; pulmonary artery hypertension; right ventricle systolic; function; soluble ST2;

Full Text:

PDF


References

  1. Post MC. Association between pulmonary hypertension and an atrial septal defect. Neth Heart J 2013;21:331-2. https://doi.org/10.1007/s12471-013-0432-9
  2. Lourenco AP, Fontoura D, Henriques-Coelho T, Leite-Moreira AF. Current pathophysiological concepts and management of pulmonary hypertension. Int J Cardiol 2012; 155:350-61. https://doi.org/10.1016/j.ijcard.2011.05.066
  3. Webb G, Gatzoulis MA. Atrial septal defects in the adult: recent progress and overview. Circulation 2006; 114:1645-3. https://doi.org/10.1161/CIRCULATIONAHA.105.592055
  4. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, Mcgoon MD, Meldrum DR, et al. Right ventricular function and failure. Circulation 2006; 114:1883-91. https://doi.org/10.1161/CIRCULATIONAHA.106.632208
  5. Januzzi J, Peacock W, Maisel A, Chae CU, Jesse RL, Baggish AL, et al. Measurement of the interleukin familymember ST2 in patients with acute dyspnea: results from the ProBNP Investigation ofDyspnea in the Emergency Department (PRIDE) study. J Am Coll Cardio 2007; 50:607-13. https://doi.org/10.1016/j.jacc.2007.05.014
  6. Carlomagno G, Messalli G, Melillo R, Stanziola A, Visciano C, Mercurio V, et al. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. Int J Cardiol 2012; 168:1545-47. https://doi.org/10.1016/j.ijcard.2012.12.031
  7. Zheng Y, Yang T, He J, Chen G, Liu Z, Xiong C, et al. Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. Clin Cardiol 2014; 37:365–70. https://doi.org/10.1002/clc.22262
  8. Dinarti LK, Hartopo AB, Kusuma AD, Satwiko MG, Hadwiono MR, Pradana AD. The COngenital HeARt Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: a descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. BMC Cardiovasc Disord 2020; 20(1):163. https://doi.org/10.1186/s12872-020-01434-z
  9. Galie N, Humbert M, Vachiery KL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37:67-119. https://doi.org/10.1183/13993003.01032-2015
  10. Hartopo AB, Sukmasari I, Puspitawati I. The utility of point of care test for soluble ST2 in predicting adverse cardiac events during acute care of ST-segment elevation myocardial infarction. Cardiol Res Pract 2018; 3048941. https://doi.org/10.1155/2018/3048941
  11. Engelfriet PM, Duffels MGJ, Moller T, Boersma E, Tijssen JGP, Thaulow E, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007; 93:682-7. https://doi.org/10.1136/hrt.2006.098848
  12. Beghetti M, Galiè N. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53:733-40. https://doi.org/10.1016/j.jacc.2008.11.025
  13. Agoston-Coldea L, Lupu S, Hicea S, Paradis A, Mocan T. Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction. Biomarkers Med 2014; 8: 95-106. https://doi.org/10.2217/bmm.13.116
  14. Poels EM, Martins PA, Empel VP. Adaptive capacity of the right ventricle, why does it fail? Am J Physiol Heart 2015; 308:H803-13. https://doi.org/10.1152/ajpheart.00573.2014
  15. Gorgulu S, Eren M, Uslu N, Ozer O, Nurkalem Z. The determinants of right ventricular function in patients with atrial septal defect. Int J Cardiol 2006; 111:127-30. https://doi.org/10.1016/j.ijcard.2005.07.037
  16. Pratama RS, Hartopo AB, Anggrahini DW, Dewanto VC, Dinarti LK. Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect. Pulm Circ 2020; 10(2):2045894020915832. https://doi.org/10.1177/2045894020915832



DOI: https://doi.org/10.19106/JMedSci005203202005

Article Metrics

Abstract views : 1350 | views : 1472


Bookmark and Share


Copyright (c) 2020 Firandi Saputra, Anggoro Budi Hartopo, Hariadi Hariawan, Dyah Wulan Anggrahini, Lucia Kris Dinarti

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.